脑心通和阿司匹林在气虚血瘀证冠心病二级预防中的疗效及不良反应比较研究
|
摘要
目的探讨脑心通和阿司匹林在气虚血瘀证冠心病二级预防中的疗效及不良反应情况。方法回顾分析本院心内科2015年9月~2017年1月收治36例气虚血瘀证冠心病患者的临床资料,随机分为A、B、C组,分别实施阿司匹林、脑心通以及脑心通+阿司匹林治疗,比较3组疗效和不良反应情况。结果 A组有效率为66.7%,中医证候疗效为66.7%,复发率为16.7%,并发症发生率为16.7%,B组有效率为66.7%,中医证候疗效为58.3%,复发率为16.7%,并发症发生率为50.0%,C组有效率为91.7%,中医证候疗效为83.3%,复发率为0.0%,并发症发生率为41.7%,3组比较差异有统计学意义(P<0.05)。结论在气虚血瘀证冠心病二级预防中应用脑心通和阿司匹林,有助于患者症状改善,且复发率和并发症发生率较低。
Objective To explore the efficacy and adverse reactions of Naoxintong and aspirin in the two level prevention of coronary heart disease with Qi deficiency and blood stasis syndrome.Methods The clinical data of 36 cases of coronary heart disease with Qi deficiency and blood stasis syndrome in our hospital from September 2015 to January 2017 were analyzed and divided into groups of A,B and C randomly.The treatment of aspirin,Naoxintong and Naoxintong+aspirin were carried out respectively,and the curative effect and ungood reaction of the three groups were compared.Results The effective rate of A group was 66.7%,the curative effect of TCM syndrome was 66.7%,the recurrence rate was 16.7%,the rate of complication was 16.7%,the effective rate of group B was 66.7%,the curative effect of TCM syndrome was 58.3%,the recurrence rate was16.7%,the rate of complication was 50.0%,the effective rate of the group C was 91.7%,the TCM syndrome was 83.3%,the recurrence rate was0.0%,the incidence of complication was 41.7%,and there was statistical difference between the three groups(P<0.05).Conclusion The application of Naoxintong and aspirin in the two stage prevention of coronary heart disease in Qi deficiency and blood stasis syndrome is helpful for the improvement of the patients'symptoms,and the recurrence rate and the incidence of complications are low.
Objective To explore the efficacy and adverse reactions of Naoxintong and aspirin in the two level prevention of coronary heart disease with Qi deficiency and blood stasis syndrome.Methods The clinical data of 36 cases of coronary heart disease with Qi deficiency and blood stasis syndrome in our hospital from September 2015 to January 2017 were analyzed and divided into groups of A,B and C randomly.The treatment of aspirin,Naoxintong and Naoxintong+aspirin were carried out respectively,and the curative effect and ungood reaction of the three groups were compared.Results The effective rate of A group was 66.7%,the curative effect of TCM syndrome was 66.7%,the recurrence rate was 16.7%,the rate of complication was 16.7%,the effective rate of group B was 66.7%,the curative effect of TCM syndrome was 58.3%,the recurrence rate was16.7%,the rate of complication was 50.0%,the effective rate of the group C was 91.7%,the TCM syndrome was 83.3%,the recurrence rate was0.0%,the incidence of complication was 41.7%,and there was statistical difference between the three groups(P<0.05).Conclusion The application of Naoxintong and aspirin in the two stage prevention of coronary heart disease in Qi deficiency and blood stasis syndrome is helpful for the improvement of the patients'symptoms,and the recurrence rate and the incidence of complications are low.
引文
[1]安琴,王晓兰,王娜,等.合并冠心病的老年H型高血压患者冠脉造影特点分析[J].当代医学,2017,23(22):98-99.
[2]张跃钢.不同类型冠心病患者血清脂联素水平和冠心病危险因素的变化及其关系[J].当代医学,2016,22(23):38-39.
[3]余帮兴.脑心通胶囊联合拜阿司匹林治疗典型急性脑栓塞的临床疗效观察[J].实用心脑肺血管病杂志,2013,21(2):115-116.
[4]杨宏武,周征成,楼小亮,等.脑心通对大鼠神经功能评分及梗死体积的影响[J].江西医药,2014,49(10):990-993.
[5]胡寿信.脑心通胶囊对老年心和脑血管事件的疗效[J].中华中医药学刊,2013,31(12):2835-2837.
[6]李继光.阿司匹林辅助脑心通治疗腔隙脑梗死110例疗效分析[J].中国实用神经疾病杂志,2013,16(11):20-21.
[7]史德海,张卉田,赵梦杨,等.脑心通胶囊联合阿托伐他汀在急性脑梗死二级预防中的作用[J].中国全科医学,2011,14(8B):2699-2700.
[8]樊萍,王荣,陈恬.缺血性卒中患者服阿司匹林致上消化道出血的风险分析[J].江西医药,2012,47(8):694-695.
[2]张跃钢.不同类型冠心病患者血清脂联素水平和冠心病危险因素的变化及其关系[J].当代医学,2016,22(23):38-39.
[3]余帮兴.脑心通胶囊联合拜阿司匹林治疗典型急性脑栓塞的临床疗效观察[J].实用心脑肺血管病杂志,2013,21(2):115-116.
[4]杨宏武,周征成,楼小亮,等.脑心通对大鼠神经功能评分及梗死体积的影响[J].江西医药,2014,49(10):990-993.
[5]胡寿信.脑心通胶囊对老年心和脑血管事件的疗效[J].中华中医药学刊,2013,31(12):2835-2837.
[6]李继光.阿司匹林辅助脑心通治疗腔隙脑梗死110例疗效分析[J].中国实用神经疾病杂志,2013,16(11):20-21.
[7]史德海,张卉田,赵梦杨,等.脑心通胶囊联合阿托伐他汀在急性脑梗死二级预防中的作用[J].中国全科医学,2011,14(8B):2699-2700.
[8]樊萍,王荣,陈恬.缺血性卒中患者服阿司匹林致上消化道出血的风险分析[J].江西医药,2012,47(8):694-695.